Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007793 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
A Phase 3 study of Primary Hyperaldosteronism, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07007793 is a Phase 3 study of Primary Hyperaldosteronism that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT07007793, a Phase 3 study of Primary Hyperaldosteronism, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and 12 countries.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baxdrostat
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - San Francisco
Illinois
- Research Site - Chicago
- Research Site - Springfield
Massachusetts
- Research Site - Boston
- Research Site - Boston
Ohio
- Research Site - Cleveland
- Research Site - Columbus
Pennsylvania
- Research Site - Bethlehem
- Research Site - Philadelphia
Connecticut
- Research Site - Farmington
Maryland
- Research Site - Baltimore
Michigan
- Research Site - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2028-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007793
The ClinicalTrials.gov registry entry for NCT07007793 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Hyperaldosteronism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07007793 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07007793 about?
NCT07007793 is a clinical study titled "A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism". This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone Syste...
What is the current status of trial NCT07007793?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-08-07. Estimated completion is 2028-02-18.
What conditions does trial NCT07007793 study?
This clinical trial studies the following conditions: Primary Hyperaldosteronism.
What interventions are being tested in trial NCT07007793?
The interventions under investigation include: Placebo (DRUG), Baxdrostat (DRUG).
Who is sponsoring clinical trial NCT07007793?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007793 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperaldosteronism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.